GLP-1 Medications and Women's Hormones: What the Research Shows

The pivotal GLP-1 obesity trials enrolled women in roughly equal proportions to men, but most of the reported outcomes pooled both sexes. The questions women bring to GLP-1 medications — about menstrual cycles, contraception, fertility, PCOS, perimenopause — sit in a literature that is real but younger than the medications themselves. The picture is filling in fast. The clinical guidance, in some areas, is ahead of the published evidence; in others, it's still catching up.

What follows is the current state of what's known, organised around the questions women most often raise with prescribers.

Polycystic ovary syndrome: the strongest evidence base

PCOS affects roughly 6–13% of reproductive-age women and combines insulin resistance, hyperandrogenism, and ovulatory dysfunction. The metabolic features overlap substantially with the targets of GLP-1 therapy, and the clinical investigations were among the earliest applications outside diabetes.

Mojca Jensterle at the University Medical Centre Ljubljana has led much of the work in this space. Her group's 2014 randomised trial compared liraglutide with metformin in obese women with PCOS and found that liraglutide produced significantly greater weight loss and a higher rate of menstrual regularity restoration. A subsequent 2020 trial extended the comparison to semaglutide with similar findings: improved insulin sensitivity, modest reductions in androgen levels, and restored ovulatory cycles in a substantial proportion of previously anovulatory participants.

The clinical implication is meaningful. For women with PCOS attempting to conceive, the return of regular ovulation can be the therapeutic goal — though pregnancy itself requires discontinuation of the medication (more on that below). For women not currently pursuing pregnancy, the metabolic improvements often coexist with subjective changes patients describe as the first time their bodies have felt regulated.

Why GLP-1 medications may work in PCOS specifically

The mechanism appears to operate on multiple fronts. Improved insulin sensitivity reduces ovarian androgen production. Weight loss itself lowers androgen levels independent of medication mechanism. GLP-1 receptors are expressed in human ovarian tissue, and animal models suggest direct effects on ovarian steroidogenesis, though the human relevance of this remains under investigation. The clinical effect is the easier finding: cycles regularise, insulin resistance improves, weight loss accumulates.

Contraception and absorption: the practical concern

Oral contraceptive absorption is affected by gastric emptying, which GLP-1 medications slow. The clinical question is whether this changes contraceptive efficacy meaningfully. The answer is medication-specific.

For semaglutide, pharmacokinetic studies have shown only minor effects on oral contraceptive absorption, and the FDA prescribing information does not require backup contraception. For tirzepatide, the picture is different. The FDA prescribing label for both Mounjaro and Zepbound explicitly recommends backup non-oral contraception for four weeks after initiation and for four weeks after each dose escalation. The basis for this recommendation is reduced peak concentrations and reduced total exposure of ethinyl estradiol and norelgestromin observed in pharmacokinetic studies during the early dose titration period.

Practically, this means tirzepatide patients using oral contraception should add a barrier method (condom) or switch to a non-oral method (IUD, implant, injection, ring, patch) during the four-week windows specified. Patients using non-oral hormonal contraception are not affected by this concern.

The pregnancy question

Both semaglutide and tirzepatide are categorised by the FDA as not recommended during pregnancy. Animal studies have shown adverse developmental effects, and human data is limited. Standard guidance is to discontinue at least two months before attempting conception for semaglutide, and at least one month before for tirzepatide — the longer window for semaglutide reflects its substantially longer half-life.

For women who become pregnant unexpectedly while on a GLP-1, the recommendation is to discontinue and notify the prescribing clinician promptly. Several pregnancy registries — including Novo Nordisk's pregnancy surveillance programme — are actively collecting outcome data, and patients are encouraged to enroll. The available human evidence so far has not shown a clear pattern of teratogenicity, though the dataset remains small and the guidance remains conservative.

Menstrual cycles and the menstrual experience

Women on GLP-1 medications report a range of changes to their menstrual experience that aren't yet well-mapped in the published literature. Some report lighter, more regular periods — particularly common in women with PCOS or those with substantial weight loss. Some report initial irregularity in the first few months as cycles adjust. Some report changes in premenstrual symptoms, often in the direction of improvement.

The mechanisms likely overlap. Weight loss itself affects the hypothalamic-pituitary-ovarian axis. Improved insulin sensitivity reduces ovarian androgen production. The direct effects of GLP-1 signalling on reproductive endocrine function in humans remain under investigation. What clinicians tend to see in practice is that menstrual changes during the first few months are common and usually settle, and that women with previously irregular cycles often see normalisation rather than disruption.

When menstrual changes warrant evaluation

New persistent amenorrhea, heavy or prolonged bleeding, or breakthrough bleeding in patients on hormonal contraception is worth raising with a clinician. These are not commonly attributed to the GLP-1 itself but may reflect concurrent factors (rapid weight loss, thyroid changes, contraceptive absorption issues) that deserve evaluation.

Perimenopause and the weight-resistance pattern

The hormonal transitions of perimenopause — declining estrogen, shifting progesterone, increasing FSH — coincide with metabolic changes that many women experience as new resistance to previously effective weight management approaches. Visceral fat accumulation increases. Insulin sensitivity often declines. Sleep disruption from vasomotor symptoms compounds the picture.

The clinical experience with GLP-1 medications in perimenopausal women has been positive, though high-quality randomised data specific to this population is still emerging. The reasoning is straightforward: the metabolic mechanisms GLP-1 medications address are precisely the ones that intensify during perimenopause. Subset analyses of the STEP and SURMOUNT trials suggest that women in the perimenopausal age range respond similarly to younger women in terms of weight loss percentages.

One consideration specific to perimenopause is the interaction with hormone replacement therapy. There is no known clinically significant interaction between systemic HRT (oral or transdermal estrogen, with or without progesterone) and GLP-1 medications. Patients on HRT can generally continue both without adjustment.

The bone density question

Rapid weight loss in any form — surgical, dietary, or pharmacological — can contribute to bone density loss. For perimenopausal and postmenopausal women, already at elevated osteoporosis risk, this consideration matters. The published bone density data on GLP-1 weight loss is reassuring but not extensive; the standard clinical recommendation is to ensure adequate calcium and vitamin D intake, prioritise resistance training, and consider DEXA monitoring for women with additional risk factors.

Fertility, sexual function, and broader hormonal context

For women not actively trying to conceive, the fertility-restoration effect of GLP-1 medications in PCOS is worth understanding. Women with anovulatory PCOS who haven't been using contraception sometimes become pregnant unexpectedly after starting treatment — the restoration of ovulation that the medication produces can precede any conscious change in family planning. Discussing contraception explicitly at treatment initiation is standard care.

Sexual function changes have been reported in both directions. Some patients describe improved libido and sexual function, often linked to weight loss and improved body image. Others report reduced libido during the early titration phase, often attributed to fatigue or generalised reward-system effects. The published data is limited and primarily based on patient-reported outcomes from quality-of-life subscales in pivotal trials.

For the broader picture on how GLP-1 medications interact with mood, motivation, and quality of life, see our piece on GLP-1 medications and mental health. The companion review of who qualifies for GLP-1 prescription covers the broader eligibility criteria, including the PCOS pathway. And our pre-GLP-1 checklist covers the practical preparation worth doing in the week before starting.

Key takeaways

• PCOS has the strongest evidence base outside diabetes — Jensterle's trials and subsequent work show improved insulin sensitivity, restored ovulation, and meaningful weight loss with liraglutide and semaglutide.
• For tirzepatide specifically, FDA prescribing information recommends backup non-oral contraception for four weeks after initiation and four weeks after each dose escalation due to reduced oral contraceptive absorption during titration.
• Semaglutide shows only minor pharmacokinetic effects on oral contraceptives and does not require backup contraception per current labelling.
• Discontinue at least two months before planned conception for semaglutide, at least one month for tirzepatide; both are categorised as not recommended during pregnancy.
• Menstrual changes in the first few months are common and usually settle; women with PCOS often experience normalisation rather than disruption.
• Perimenopausal women respond well to GLP-1 medications in trial subset analyses; no clinically significant interactions with HRT have been identified.
• Rapid weight loss in any form can affect bone density — adequate calcium, vitamin D, and resistance training are particularly relevant for peri- and postmenopausal patients.